| Urologic Neoplasms |
NCT00589017: Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy |
|
|
| Recruiting | 2 | 75 | US, Europe | tamoxifen citrate, immunohistochemistry staining method, laboratory biomarker analysis | Baylor College of Medicine | Bladder Cancer | 07/10 | | | |
| Active, not recruiting | 2 | 64 | Europe | Standard planning radiotherapy, Adaptive planning radiotherapy | Institute of Cancer Research, United Kingdom, Cancer Research UK | Bladder Cancer | 07/17 | 01/25 | | |
NCT00915993: MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer |
|
|
| Recruiting | N/A | 40 | US | sunitinib malate, mutation analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging | University of Pennsylvania, National Cancer Institute (NCI) | Kidney Cancer | 05/11 | | | |
NCT00655252 / 2007-005460-28: Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy |
|
|
| No Longer Available | N/A | | US, Canada, Europe, RoW | Everolimus | Novartis Pharmaceuticals | Metastatic Renal Cell Cancer | | | | |
|
|
|
NCT01956253: Single Subject Neratinib in Bladder Cancer (NRR) |
|
|
| No Longer Available | N/A | | US | Neratinib | UNC Lineberger Comprehensive Cancer Center | Bladder Cancer | 09/13 | 06/14 | | |
NCT01473043: Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment |
|
|
| No Longer Available | N/A | | Canada, RoW | Axitinib, AG-013736 | Pfizer | Renal Cell Carcinoma | 03/14 | 03/14 | | |
NCT02186925: A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney. |
|
|
| Recruiting | N/A | 1000 | RoW | | Meir Medical Center | Kidney Cancer, Prostate Cancer, Bladder Cancer | 08/19 | 08/25 | | |